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ABSTRACT
Introduction: Comparative effectiveness research (CER) seeks to inform
clinical decisions between alternate treatment strategies using data that
reﬂects real patient populations and real-world clinical scenarios for the
purpose of improving patient outcomes. There are multiple clinical situa-
tions where the unique characteristics of observational investigations can
inform medical decision-making within the CER paradigm. Accordingly, it
is critical for clinicians to appreciate the strengths and limitations of
observational research, particularly as they apply to CER.
Methods: This review focuses on the role of observational research in
CER. We discuss the concept of evidence hierarchies as they relate to
observational research and CER, review the scope and nature of observa-
tional research, present the rationale for its inclusion in CER investiga-
tions, discuss potential sources of bias in observational investigations as
well as strategies used to compensate for these biases, and discuss a
framework to implement observational research in CER.
Conclusions: The CER paradigm recognizes the limitations of hierarchical
models of evidence and favors application of a strength-of-evidence model.
In this model, observational research ﬁlls gaps in randomized clinical trial
data and is particularly valuable to investigate effectiveness, harms, prog-
nosis, and infrequent outcomes as well as in circumstances where random-
ization is not possible and in studies of many surgical populations.
Observational investigations must be designed with careful consideration
of potential sources of bias and must incorporate strategies to control such
bias prospectively, and their results must be reported in a uniform and
transparent fashion. When these conditions can be achieved, observational
research represents a valuable and critical component of modern CER.
Keywords: clinical investigation, comparative effectiveness research,
evidence-based medicine, observational research, outcomes research.
Introduction
Comparative effectiveness research (CER) is deﬁned by the Insti-
tute of Medicine (IOM) as, “the generation and synthesis of
evidence that compares the beneﬁts and harms of alternative
methods to prevent, diagnose, treat, and monitor a clinical con-
dition or to improve delivery of care [1]” and by the Federal
Coordinating Council for Comparative Effectiveness Research
[created by the US Congress [2]] as, “the conduct and synthesis
of research comparing the beneﬁts and harms of different inter-
ventions and strategies to prevent, diagnose, treat, and monitor
health conditions in “real world” settings [3].” The purpose of
CER, as stated by the IOM, is “to assist consumers, clinicians,
purchasers, and policy makers to make informed decisions that
will improve health care at both the individual and population
levels [4].” CER therefore seeks to inform clinical decisions
between alternate management strategies using data that reﬂects
real patient populations and real-world clinical scenarios for the
purpose of improving patient outcomes.
The potential for such a strategy to advance the public health
while simultaneously decreasing health-care expenditure has cap-
tured the attention of health policymakers, and over the past
several years, the CER paradigm has become part of the national
discourse regarding strategies to reﬁne the US health-care system.
The connection between cost-effectiveness research and value-
based medicine and CER has caused a degree of clinician and
public skepticism of this model, but the overall CER paradigm
reaches far beyond cost considerations. Recognizing the limita-
tions of randomized controlled trials, CER has directed new
emphasis on problem-based research and practical clinical trials
as well as on observational studies that ﬁll knowledge voids left
by randomized clinical trials. Utilizing all of these modalities,
CER seeks to combine treatment efﬁcacy data with quality of life,
outcomes, and other forms of effectiveness data to guide selection
of optimal patient management strategies.
The concept of evidence-based medicine (EBM) is familiar to
most clinicians, and often, those who encounter CER in the
literature erroneously conceptualize EBM and CER as different
versions of the same research paradigm. This is inaccurate, as
EBM focuses primarily on demonstrating efﬁcacy of treatment
modalities, whereas CER attempts to inform clinical decisions
regarding patient management. One of the most signiﬁcant dif-
ferences in the two research models is the role of observational
research. Frequently marginalized in EBM as low-quality and
suboptimal, observational research is gaining prominence as an
expeditious and cost-effective modality to inform large numbers
of real-world patient management decisions in the CER para-
digm [4], which recognizes that there are multiple clinical situa-
tions where the unique characteristics of observational
investigations can inform the decision-making process.
In this review, we highlight the role of observational research
in the CER paradigm. We will review the scope and nature of
observational research, present the rationale for its inclusion in
CER investigations, and discuss a framework for its implemen-
tation. This discussion will also highlight the important differ-
ences between CER and EBM that are often underappreciated by
clinicians.
Hierarchical Models of Evidence and CER
Discussing the role of observational research in CER requires
ﬁrst addressing the concept of evidence hierarchies, because one
critical step in moving from an EBM to a CER paradigm is
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rethinking the hierarchical scheme to stratify levels of clinical
evidence upon which most EBM reviews are based. The hierar-
chical system utilized in the EBM model deﬁnes ﬁve levels of
evidence. Randomized clinical trials (and systematic reviews
thereof) are assigned to level 1, representing the highest grade of
available evidence. Level 2 generally reﬂects cohort studies, level
3 represents case-control studies, and levels 4 and 5 are reserved
for case series and expert opinions, respectively [5]. Inherent in
this scheme is the belief that studies in a given level are method-
ologically superior to those assigned to lower levels and therefore
yield higher quality, less biased results [6]. This model has gained
widespread acceptance since a landmark paper in 1982 [7] dem-
onstrated relative reductions in selection bias resulting from
application of the randomized, controlled design, but recent
theoretical concerns and empiric investigations have challenged
the universal supremacy of the randomized clinical trials (RCTs).
In so doing, they have also called into question the validity of a
rigid, hierarchical model of clinical evidence.
Theoretical challenges to the hierarchical evidence model
question the validity of the assumptions upon which RCTs are
based. First, RCTs assume a state of clinical equipoise [8–10] that
is typically attributable to a lack of sufﬁcient scientiﬁc knowledge
to deﬁnitively recommend one management strategy over
another. In practice, however, the validity of this assumption may
be questionable because the existing body of clinical investiga-
tions relative to a speciﬁc treatment is rarely completely neutral
and true clinical equipoise may be relatively uncommon
[9,11,12]. Next, the balance between the magnitude of speciﬁc
and nonspeciﬁc effects of alternate treatment modalities can
inﬂuence the statistical signiﬁcance and thus the conclusions of
RCTs, giving rise to the so-called “efﬁcacy paradox” [11]. RCTs
are typically optimized to detect differences in the magnitude of
speciﬁc treatment effects while neglecting nonspeciﬁc and overall
treatment effects, yet it is the latter that has been shown to be of
greatest interest to patients [13–15]. Finally, the context in which
the treatment is provided in RCTS as well as the external validity
of the conclusions drawn by these studies must be carefully
interpreted, as studies have shown that contextual therapeutic
messages and beliefs can affect measured treatment efﬁcacy
[16–19] and that selection biases [20] and incongruities in study
versus clinical patient populations [21,22] can affect external
validity [11]. Whereas RCTs remain a critical and time-tested
tool for conducting high-quality medical research, these concerns
regarding the assumptions necessary for RCT validity suggest
that alternate research modalities may be necessary to inform
clinical decisions, particularly in clinical situations where one or
more of the aforementioned preconditions for RCT validity are
clearly violated.
Objective attempts to study the alleged superiority of RCTs
have also called into question the position of RCTs at the top of
an evidence hierarchy [23]. Multiple investigations comparing
RCTs to well-designed, nonrandomized trials have consistently
demonstrated high degrees of concordance in the trial results
[6,24–28], demonstrating that RCTs are not necessarily superior
to other modalities in their ability to produce valid clinical
results. Additionally, comparisons of multiple RCTs that address
similar clinical questions have demonstrated signiﬁcantly discor-
dant results [29], highlighting the fact that RCTs do not de facto
provide deﬁnitive and incontrovertible results. Taken together,
these ﬁndings suggest that designation of RCTs as the gold stan-
dard for clinical research in every and all cases may be uncertain
and that alternate research designs may be equally or, at times,
more appropriate to address speciﬁc clinical questions.
If the current state of clinical trial design is such that there is
neither a single, gold-standard modality that ﬁts all clinical ques-
tions nor deﬁnitive evidence of superiority among well-
constructed investigations using alternate study design models,
then the validity and utility of a hierarchical stratiﬁcation of
evidence may need to be reexamined in certain cases [6,11,30].
Several authors have argued for alternate models that inform
clinical decisions by emphasizing the appropriateness of study
design to the clinical question and the quality of the individual
investigations rather than their hierarchical stratiﬁcation [6].
This approach, sometimes described as a circular model of evalu-
ation [11], has been applied in the social sciences and alternative
medicine for some time [31–35]. These models acknowledge that
there may be different optimal approaches to answer different
clinical questions and that a composite of such investigations
may provide a more comprehensive basis to inform clinical deci-
sions than any one investigation alone.
The CER enterprise in the United States has recognized these
concerns and has approached this issue by adopting a strength-
of-evidence model rather than a level-of-evidence model. The
United States Agency for Health Care Research and Quality
(AHRQ) notes that, while evidence hierarchies focus primarily
on study design, strength-of-evidence models focus on several
additional domains to ensure methodological consistency to
grade evidence and to facilitate more uniform interpretation of
the meaning of evidence grading by end users of these data
[36,37]. Based on evidence analysis performed by the US Pre-
ventive Services Task Force [38] and the Grading of Recommen-
dations Assessment, Development and Evaluation working
group [39], the AHRQ recommended analysis of four “required
domains” when determining the strength of evidence in CER
investigations: risk of bias, consistency between studies of similar
questions, directness of association between interventions and
outcomes of interest, and precision of evidence for anticipated
outcomes [36]. Secondary domains, including dose–response
associations, existence of confounders, magnitude of effect, and
publication bias, can be included, when applicable, to describe
the strength of evidence more robustly. A strength-of-evidence
analysis results in classiﬁcation of evidence into one of four
grades, which describe the general magnitude of conﬁdence that
the evidence reﬂects a true effect. Evidence can be assigned a
designation of high, moderate, or low or can be designated as
insufﬁcient to provide a conclusion [36]. More detailed guide-
lines for constructing and interpreting strength-of-evidence
analyses have been produced by the AHRQ [36], and such analy-
ses represent an important dimension of CER. The decision to
follow a strength-of-evidence model presents an opportunity for
well-designed, observational studies to assume a more prominent
role in CER.
Observational Studies and CER
Deﬁnitions
The term, “observational research,” has classically been used to
describe investigations where the researcher observed but did not
interact with the study population, and it is still often applied this
way in social science [40] and business and economics research
[41]. Although there remains some variability in nomenclature,
the term “observational research,” is typically used in modern
biomedical research to refer to investigations conducted on
samples whose membership has not been affected by the inves-
tigator. In this manifestation, observational research is held in
contrast to randomized trial research, wherein the investigator
uses a process of randomization to assign participants to speciﬁc
management groups. Because such assignment does not occur in
observational studies, the terms “nonrandomized research,”
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“nonrandomized trials,” or “nonexperimental research”
are often considered to be functionally interchangeable with
“observational research” [42].
Observational studies can be divided into prospective or ret-
rospective analyses. Retrospective, observational analyses iden-
tify a sample of patients with a known outcome and seek to
determine the nature and frequency of a given exposure that
preceded the outcome. Similar investigation of exposure in a
sample without evidence of the outcome may be used to study the
outcome frequency in the general population. Members of the
sample group exhibiting the outcome in question are referred to
as cases, whereas those without the outcome of interest are
considered controls. This designation gives rise to the term case-
control study and describes one form of retrospective, observa-
tional research [42]. Other forms include case series and single
case reports reviewed in a retrospective fashion, as well as
research derived from retrospectively collected databases. Inci-
dence rates cannot be determined from this model, but the
measure of association between exposure and outcome can be
investigated in case-control studies and is expressed as the odds
ratio [43,44].
In contrast, prospective, observational analyses follow over a
period of time or to a speciﬁc end point a predetermined sample
of patients who have been exposed to some factor under inves-
tigation. These studies can be descriptive in nature, reporting
outcomes in the group after exposure to the factor without
direct, statistical comparison to a control sample, or can be
analytic in nature, using comparison between the experimental
sample and a control sample to calculate the probabilistic rela-
tionship between exposure and outcome [42]. The former is
described as a prospective case series, whereas the latter are
called cohort studies in reference to the cohort of patients that is
being followed. Whereas case series are not used to calculate
analytic epidemiologic statistics, cohort studies can be used to
measure the incidence rates in the two populations as well as the
relative risk of outcome associated with exposure [42,45].
Bias and the Limitations of Observational Studies
All studies, regardless of design, are subject to similar potential
sources of bias. The Cochrane Collaboration [46], the United
Kingdom’s National Institute for Health and Clinical Excellence
[47], and other evidence-based research bodies have organized
the major sources of bias in clinical investigations into four
categories. Like all study designs, observational investigations
have some limitations in their ability to fully address these biases.
Understanding the effects of such bias and the strategies used to
limit these effects is critical to performing high-quality observa-
tional research.
Selection bias is deﬁned as a distorted estimate of the effect
that results from the way in which subjects are selected for the
study population [48]. Selection bias is often attributable to the
presence of confounding variables (confounders), deﬁned as
extraneous variables that correlate with both the dependent and
the independent variable(s). In order to be truly confounding, a
variable must satisfy two conditions; it must be a risk factor for
the outcome being studied and it must be associated with, but not
a consequence of, the exposure being examined [49]. Closely
related and commonly misunderstood is the concept of con-
founding by indication. This term describes the presence of an
extraneous determinant of the outcome parameter that is present
if a perceived high risk or poor prognosis is an indication for
intervention [9,10,37,48,50,51]. In this circumstance, the indi-
cation correlates with the intervention and is a risk for the illness,
qualifying it as a confounder and producing an imbalance in
prognostic factors between comparison groups [48]. Randomiza-
tion minimizes selection bias and theoretically eliminates con-
founders and confounding by indication, whereas the lack of
randomization in observational investigations makes them par-
ticularly susceptible to these sources of bias. Control of known
confounders can minimize these effects in cohort studies, and
matching can address similar issues in case-control investigations
[46,52]. Unknown or unmeasured confounders, however, cannot
be addressed in this fashion, and the inability of observational
studies to address such bias represents the most signiﬁcant limi-
tation of this study design.
Performance bias refers to systematic differences in care other
than intervention under investigation that is provided to study
participants, whereas detection bias describes systematic differ-
ences between comparison groups in outcomes assessments [46].
Both of these biases are addressed in RCTs by blinding, but
complete blinding is usually not possible in observational
research. Performance bias is addressed in observational studies,
including both cohort and case-control studies, by measuring the
exposure to the intervention of interest and ensuring that differ-
ences in the exposure of the comparison groups either did not
exist or did not affect the investigational outcomes. Cohort
studies can implement limited blinding strategies to reduce detec-
tion bias, whereas case-control studies must rely on the case
deﬁnition to reduce this bias [46,47,52]. Limitations on blinding
and the resulting reduced control of performance and detection
biases represent additional limitations of observational studies.
Attrition bias refers to systematic differences in the loss of par-
ticipants between the comparison groups [46,52]. Attrition has
signiﬁcant potential to affect all types of clinical trials, regardless
of design. Close and meticulous follow-up is the best strategy to
limit the effects of attrition bias in both randomized controlled
trials and in observational research [46,52].
Advantages of Observational Studies
Despite having some vulnerability to the aforementioned sources
of potential bias, observational studies are well suited to inves-
tigate certain types of clinical questions that cannot be
adequately addressed by RCTs alone [53,54]. Several examples
of clinical situations where observational investigations can
provide clinical relevant data beyond that afforded by traditional
RCTs are as follows:
Investigations of effectiveness. RCTs are designed for the speciﬁc
purpose of evaluating the efﬁcacy of a particular treatment, or
the extent to which the treatment under study produces the
intended effect in an ideal setting. Such studies use homogeneous
populations, under carefully controlled conditions, to study a
limited number of immediate or short-term outcomes. Effective-
ness studies, which are central to CER, have the more complex
goal of assessing the beneﬁcial effects of the particular treatment
in the context of everyday practice [39]. Here, the patient popu-
lation is more heterogeneous, conditions are less controlled, and
multiple variables may impact the outcomes. Studying the ben-
eﬁcial effects of therapy therefore frequently requires larger
sample populations that are followed over longer periods of time,
a situation well suited for observational research (particularly
prospective trials and patient databases). Additionally, effective-
ness research requires that the effects of a number of potential
variables and confounders be analyzed rather than eliminated.
This includes variables introduced by the complex decision-
making processes of actual caregivers, which may encompass any
of a number of factors that motivate decisions regarding selec-
tion, initiation, adjustment, or cessation of therapy [55]. Such
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scenarios require the type of comprehensive data collection that
is characteristic of observational research. Ultimately, effective-
ness trials attempt to assess the overall degree of beneﬁt in “real
world,” clinical settings and to improve the generalizability, or
external validity, of RCTs [30,55–58]. This is central to the
mission of CER and is a major reason why observational
research has an important role in this paradigm.
Investigation of harms. If effectiveness research is conceptual-
ized as focusing on the real-world beneﬁts of a particular treat-
ment, then harms investigations can be conceived as the inverse,
focusing on the potential negative consequences of the treatment
[59]. Like effectiveness research, reliance on RCTs for harms
investigations has several fundamental limitations. In addition to
considerations of sample size [60] and homogeneity [61], dura-
tion of study [60], and ability to examine multiple variables [10],
RCTs are further limited in harms investigation because they lack
speciﬁc hypotheses designed to identify adverse events [62].
Instead, identiﬁcation of such harms represents a secondary con-
sideration in most RCTs. They are therefore either underpowered
for or biased against harms detection by virtue of their design,
which results in inadequate or incomplete harms reporting
[63–66]. Finally, RCTs do not generally compare the results of
alternate treatment strategies [67,68], so information regarding
relative harms is almost never available from such investigations.
In contrast, observational studies are well suited to address all of
these concerns [9,10,30,59]. Sample size, homogeneity, and dura-
tion of study have been addressed for effectiveness studies, and
similar reasoning is applicable to the advantages of observational
research in detection of harms. Additionally, observational
studies can be designed to identify speciﬁcally and in detail the
spectrum of novel harms that may be associated with a particular
treatment or to further investigate the relative frequency of
known harms [59]. Finally, observational designs are particularly
well suited to hypothesis testing regarding differential risk of
speciﬁc harms associated with alternate interventions [59]. All of
these factors are essential to CER and represent another valuable
contribution of observational research.
An example of the important contribution of observational
studies in assessing potential harms is the identiﬁcation of the
increased risk of myocardial infarction associated with the drug,
rofecoxib (Vioxx®). After a 6-month priority review completed in
May of 1999, rofecoxib became the second cyclooxygenase-2
inhibitor approved for symptomatic treatment of osteoarthritis
[69]. The Vioxx Gastrointestinal Outcomes Research study of
2000 [70] identiﬁed a potentially increased risk of myocardial
infarction in patients taking rofecoxib. This was attributed by the
manufacturer (Merck, Whitehouse Station, NJ) to a cardiopro-
tective effect of the control drug, naproxen, a claim that was
ultimately refuted using a meta-analysis of 11 observational
investigations [71]. Observational research played an even more
signiﬁcant role when the Federal Drug Administration’s (FDA’s)
Dr. David Graham lead a collaborative effort with Kaiser Perma-
nente of California to perform a retrospective review of cardiac
complications in patients taking rofecoxib [69]. The results of
this nested case-control study of 2,302,029 person-years of
follow-up data demonstrated an increased risk of “serious coro-
nary heart disease” in users of rofecoxib (odds ratio 1.59) [72]
and led to Merck’s voluntary withdrawal of rofecoxib in 2004
[69].
Investigations of delayed or infrequent harms. Although these
studies can be considered a subtype of harms investigations, they
merit brief, individual attention because they represent a circum-
stance where all of the aforementioned beneﬁts of observational
research (in both effectiveness and harms analyses) are simulta-
neously realized. Here, the size, heterogeneity, and time limita-
tions of RCTs combine with their lack of harms hypotheses and
comparative effectiveness abilities to produce a situation where
data on infrequent harms would be essentially impossible to
collect. In practice, it is estimated that effects that take longer
than 1 year to develop or harms that occur at a rate less than 1
per 200 per year are not adequately detected by RCTs [73].
Observational research, either prospective or retrospective, can
be applied to large, heterogeneous groups over long periods of
time to identify such delayed or infrequent harms [74–76].
Examples of the use of observational research to identiﬁed
delayed outcomes include identiﬁcation of the link between
diethylstilbestrol treatment and clear cell vaginal carcinoma
[77–79], and observational analysis has provided information
regarding the infrequent but signiﬁcant associations between
childhood aspirin use and Reye’s syndrome [54,80,81] and
between hypertrophic cardiomyopathy and sudden cardiac death
in young athletes [54,82].
Investigations of prognosis and long-term or infrequent out-
comes. Similar logic can be applied to studies of delayed or
infrequent outcomes. Because of time and sample size limita-
tions, respectively, RCTs are not well suited to investigating such
outcomes. Accordingly, identiﬁcation of long-term beneﬁts or
infrequent outcomes is difﬁcult using the RCT model. Observa-
tional studies are more appropriate to answer these questions
[74,75]. Long-term prognosis can be considered a more general
category of delayed outcome given an exposure, and similar logic
can be applied. Numerous outcomes studies have been per-
formed using this model, particularly those that involve the sur-
gical management of uncommon conditions [83] or the
durability of surgical repairs or constructs [84].
Investigations without randomization. Randomization mini-
mizes selection bias and is fundamental to the design of RCTs, but
there are four situations where randomization cannot or need not
be applied. Observational research, however, can be used in all
four situations. First, there are circumstances where randomiza-
tion is not necessary [30]. This generally occurs when two condi-
tions are met; the effect under study is dramatic and the chance of
confounding factors is negligible. In this situation, a well-
constructed, observational study is sufﬁcient to demonstrate
effectiveness [74,75]. Second, there are situations where random-
ization may be considered impossible. Several factors can lead to
this situation, including refusal by clinicians or patients to partici-
pate in a proposed trial, political or legal obstacles to randomiza-
tion, or logistical issues relating to cost or availability of resources
[74]. In all of these situations, observational research may remain
a viable alternative. Third, there are circumstanceswhere random-
ization into a clinical trial is considered unethical [8,85,86]. This
may include questions of true equipoise, issues of clinician or
researcher bias, considerations of patient safety or autonomy, and
myriad other potential ethical dilemmas [74,75]. When random-
ization has been determined to be unethical, observational studies
may be viable options for securing the best possible clinical
evidence within the conﬁnes of the existing ethical limitations.
Fourth, there are circumstances where randomization would
prove to be self-defeating. In trials where the effectiveness of the
intervention depends on the subject’s active participation in or
knowledge of the treatment, randomization either becomes
impossible or biases the results. Observational research allows for
subject participation or knowledge while retaining the ability to
measure outcomes [74]. All of these “real-world” situations may
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arise in CER, and observational studies are the appropriate tools
to address these clinical circumstances.
Investigations in surgical populations. Patients undergoing sur-
gical procedures represent a unique clinical circumstance, and
investigations of these patients have classically favored observa-
tional research. Historically the indications for surgery have been
dogmatic in some cases, as have the speciﬁc management strat-
egies implemented by the surgeon [87]. This has drawn criticism
from advocates of RCTs, who argue that randomized trials
should occupy a more prominent role in surgical decision-
making [87]. Although surgeons are beginning to embrace more
objective outcomes research, several practical counterarguments
have been made against requiring routine use of RCTs in surgical
specialties. First, although basic surgical procedures may ﬁt into
an RCT model, complex or potentially hazardous interventions
with serious immediate and long-term consequences have made
surgeons and patients [88] wary of the role of RCTs and reluc-
tant to accept random assignment of treatment [75]. Next, many
conditions managed surgically are either relatively rare or are
highly individual, reﬂecting the unique anatomic and physiologic
consequences of the patient’s disease. The same is true for the
adverse outcomes of surgical procedures, which are highly
dependent upon the individual characteristics of the patient, his
pathology, and the surgeon’s judgment and skill. RCTs are not
typically designed to identify rare events that are not easily
classiﬁed (see above) and therefore may not be the ideal modality
to investigate many surgical procedures [88,89]. Third, the com-
bination of long historical experience with surgical management
of common conditions combined with the self-evident, prompt,
and often dramatic nature of surgical results may argue against
the necessity of RCTs for many surgical conditions [87]. Fourth,
the logistics and cost associated with conducting surgical RCTs
may be so pronounced that such studies become practically
impossible [87,88,90]. Because of these circumstances, it has
been estimated that only 40% of surgical treatment questions
would be amenable to investigations with RCTs [88] and that
only 3% to 9% of currently published surgical investigations
utilize this research model [90]. As a result of a combination of
patient preference, surgeon’s attitudes and training, and the
logical arguments outlined herein, it is likely that observational
research will remain a mainstay of CER in the surgical popula-
tion for the foreseeable future.
Investigations using patient registries and databases. Patient reg-
istries prospectively compile data related to patient outcomes
after particular exposures, treatments, or procedures. These
datasets are typically comprehensive, including data compiled
from medical records, direct patient interactions, and long-term
follow-up. In addition, they are often supplemented with or
linked to additional administrative information, including
detailed demographic information, data on proxy outcomes, and
measurements of health-care resource utilization. More recently,
such databases have also begun to include information on per-
formance outcomes and on quality of life. These databases are
usually constructed for speciﬁc research purposes, but their
application can extend well beyond their original, intended
purpose. They serve as valuable repositories of comprehensive
clinical information and are considered among the strongest
sources of data for observational research [9,59]. Examples of
the value of observational, database research include character-
ization of the side effects of prostate surgery [91,92] and identi-
ﬁcation of the risk of upper gastrointestinal events associated
with bisphosphonates [93].
Additional investigations. The aforementioned examples
describe clinical situations where observational investigations are
either superior to RCTs or provide valuable, supplemental clini-
cal evidence. Additional applications of observational research
include investigations of models for diagnosis [37,73], investiga-
tions designed to clarify outcomes of RCTs, development of
strategies to identify research priorities based upon current clini-
cal knowledge, and applications in health-care policy [75]. The
details of these applications are beyond the scope of this review,
but the ultimate message is that there are multiple clinical situ-
ations where the unique characteristics of observational investi-
gations can inform medical decision-making. Vandenbroucke
summarizes this view well: “when making medicine singularly
dependent on randomized trials . . . I am not certain that the best
interest of the patient is served. Moreover, by taking away cred-
ibility from case-control research . . . the patient and the physi-
cian are left defenseless a second time [94].”
Reporting and Quality Assessment Tools for
Observational Studies
Observational studies are susceptible to multiple potential
sources of bias and confounding, so concerns regarding the
quality, validity, and reliability of data gathered from such
studies are both abundant and well-founded. As the number of
observational studies reported in the literature continues to grow,
the need for both authors and consumers of health-care informa-
tion to determine the quality of observational investigations
becomes progressively more apparent. This is particularly impor-
tant in today’s research environment, where evolving trends
toward aggregating results of empiric studies into systematic
reviews and meta-analyses have lead to an emerging body of such
literature that includes observational studies [95]. A study mea-
suring the magnitude of this effect noted that from 1955 to 1992,
there were a total of 678 published meta-analyses of observa-
tional studies, while 525 were reported from 1992 to 1995, and
400 were reported in 1996 alone [96].
Proponents of including observational data in meta-analyses
and systematic reviews cite many of the strengths of observa-
tional data discussed above as compelling reasons for the inclu-
sion of such data in evidence that informs medical decisions. This
position is supported by investigations comparing meta-analyses
based on RCTs to those based on “high-quality” observational
studies, which demonstrate similar estimates of effect from both
[24,25,97,98]. Critics of inclusion of observational data in meta-
analyses and systematic reviews cite evidence of compounding
effects of bias and confounding that can lead to potentially
distorted conclusions in such analyses [95,99]. In an effort to
reconcile these positions and to ensure reporting of reliable data,
a considerable amount of attention has focused on developing
and validating tools to assess the quality of observational inves-
tigations [100–103].
Before discussing tools for quality assessment in observa-
tional research, it is important to deﬁne the concept of quality.
Although it can be an amorphous concept, “quality” typically
refers to “susceptibility to bias [101].” This deﬁnition notwith-
standing, many quality metrics include considerations of factors
not directly related to bias, including sample size, power calcu-
lations, and ethical considerations. Additionally, it is important
to distinguish between performance quality and reporting
quality. The former refers to study design and implementation
that limits bias, whereas the latter refers to adherence to com-
prehensive reporting standards that make research transparent
but do not necessarily modulate the effects of bias [101,104].
Efforts to improve both dimensions of quality in observational
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studies have been well described but remain an area of active
investigation.
Tools to assess the quality of performance, or susceptibility
to bias, often take the form of numeric scales, checklists, or
checklists with a summary judgment [101]. A recent review of
such metrics for observational research identiﬁed 86 tools for
quality of performance assessment [101], although the number
of such metrics continues to rise. These tools assess selection
methods, measurement of study variables, design-speciﬁc
sources of bias, control of confounders, and application of sta-
tistical methods. The design process, scope, and generalizability
were variable among these tools. Approximately half of the
quality metrics assessed what are considered to be the three
fundamental quality assessment domains, including patient
selection, appropriate measurement of variables, and appropri-
ate control of bias and confounding [101]. Overall, there is a
belief that authors of observational studies should use some
form of quality of performance assessment tool, although there
has been no consensus on a single tool that most reliably
achieves this goal [101,103].
Quality of reporting must also be assessed when interpret-
ing observational research. Investigations regarding this dimen-
sion of quality have demonstrated that important information
on study design is often not reported in observational literature,
including eligibility criteria [103], methods used to identify the
study and control populations [105], and rationale behind the
choice of potential confounding variables [106]. Omission of
these data makes critical interpretation of this literature difﬁcult
[102], which may result in delayed realization of the beneﬁts of
the investigations [107]. Based upon these ﬁndings and utilizing
consensus models adopted for reporting systematic reviews
(QUOROM) [108], randomized trials (CONSORT)
[52,109,110], and studies of diagnostic tests (STARD) [111],
quality of reporting standards have been proposed for obser-
vational investigations. The Strengthening the Reporting of
Observational Studies in Epidemiology consensus statement
[102] produced a checklist of 22 items that outline speciﬁc
reporting methods and standards for observational studies.
These items include detailed recommendations regarding
reporting of the title, abstract, introduction, methods, results,
discussion, and additional information in observational
research [102]. Similar efforts to standardize reporting of meta-
analyses of observational investigations have been made by the
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) group [100], who generated a 35-item checklist cov-
ering reporting in the domains of background, search strategy,
methods, results, discussion, and conclusions for such meta-
analyses [100]. The extent to which these recommendations
will be adopted by the scientiﬁc community remains to be seen,
but these efforts demonstrate the emerging emphasis placed
on quality of performance and reporting in observational
investigations.
Applying Observational Investigation to CER
The preceding discussion has reviewed the strengths and limita-
tions of observational studies and has highlighted the potential
role for such investigations in patient-centered CER. Successful
use of observational studies in CER, however, requires selection
of appropriate clinical questions to which this methodology
should be applied and, subsequently, application of a logical
framework for implementing the research plan. This issue has
been studied independently by the AHRQ [9,10] and the inves-
tigators of the Good Research for Comparative Effectiveness
(GRACE) initiative [55]. Both agencies have issued guidelines for
implementation of observational investigations in CER, which
are summarized as follows:
I. Utilize a logical approach to identify evidence gaps where
observational studies may be particularly applicable,
including situations where:
a. Determinants of use are not related to determinants of
outcome: This often occurs when treatment decisions
are primarily affected by reimbursement patterns,
patients’ insurance coverage, or drug formularies. Bias
is reduced when experimental groups are divided
along these lines because there is theoretically little
inﬂuence between group membership and clinical
outcomes.
b. Determinants of treatment are inconsistent or
unknown: This occurs in situations of clinical equi-
poise or when there is a pure lack of appropriate
evidence to inform clinical decisions. In these circum-
stances, treatment is largely dictated by clinician pref-
erence, and outcomes from different management
strategies can be readily compared.
c. Treatment decisions are made based upon factors
unrelated to the outcomes of interest: When treatment
is initiated, adjusted, or discontinued because of a
factor unrelated to the outcome of interest, distinct
clinical groups can be segregated based upon a factor
not related to the outcome under study.
d. Little relevant information is available and there is
need of preliminary evidence: In this situation, obser-
vational investigations may be reasonable initial
studies to uncover some fundamental information
related to the clinical question at hand, which can then
be used to guide more focused investigation.
II. Prepare a study plan in advance. High-quality observational
research typically results from careful planning and meticu-
lous study design. This represents an aggressive attempt to
identify and control bias and confounders by:
a. Deﬁning the hypothesis and purpose;
b. Identifying the populations, treatments, and
comparators;
c. Deﬁning the outcomes that will be used to measure
effectiveness of each treatment;
d. Considering the necessary sample size and performing
power calculations.
III. Collect clinically relevant data as efﬁciently as possible.
In preparation for and during the process of data
collection, it is necessary to evaluate and reevaluate the
following:
a. Inclusion criteria and enrollment;
b. The speciﬁc data that will be (are being) collected
and the checks in place to assure validity of this
data;
c. Potentially useful data that are not being captured.
IV. Analyze data using a patient-centered model. Here, it is
important to ensure that the data being analyzed and the
resultant conclusions reﬂect “real-world” circumstances
and are patient-centric. This involves asking questions, such
as:
a. Do the study results reﬂect outcomes of actual treat-
ment that has been delivered? As opposed to intention-
to-treat analyses, CER must study treatments that
have actually been administered.
b. Have people with similar clinical characteristics,
including disease severity and opportunities for treat-
ment, been studied?
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c. How well have alternate explanations for the ﬁndings
been considered and how carefully have potential
biases been investigated and controlled?
This model, which has been forwarded primarily by the
GRACE initiative [55], speciﬁcally highlights fundamental issues
of good study design as applied to observational studies in CER.
Although the exact model for implementing observational
research in CER studies will vary with the particular clinical
question and research environment, the central principle remains
that such research will be most valuable when it is used to
address gaps in the existing literature, is targeted to clinical
situations for which observational research is appropriate based
upon considerations of its strengths and limitations, and remains
patient-centered.
Conclusions
The comparative effectiveness (CER) paradigm recognizes the
limitations of hierarchical models of evidence, particularly in
patient populations that are not well represented in RCT design
and in clinical circumstances where the necessary preconditions
for RCT validity are not met. Instead, CER favors application of
a strength-of-evidence model where observational investigations
occupy an important role to ﬁll knowledge voids left by RCTs.
Observational research is particularly valuable to investigate
effectiveness, harms, prognosis, and infrequent outcomes as well
as in circumstances where randomization is not possible and in
many studies of some surgical populations. Observational inves-
tigations must be designed with careful consideration of potential
sources of bias and must incorporate strategies to control such
bias prospectively, and their results must be reported in a uniform
and transparent fashion. When these conditions can be achieved,
observational research represents a valuable and critical compo-
nent of modern CER.
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